Hyloris Pharmaceuticals SA reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 1.16 million compared to EUR 1.03 million a year ago. Net loss was EUR 6.63 million compared to EUR 4.94 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.7 EUR | -1.27% | -.--% | -8.24% |
03-14 | Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024 | CI |
03-14 | Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.24% | 351M | |
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+2.04% | 224B | |
+13.31% | 218B | |
+8.48% | 168B |
- Stock Market
- Equities
- HYL Stock
- News Hyloris Pharmaceuticals SA
- Hyloris Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2023